*By Michael Teich* Republicans are struggling to renege on a long-standing pledge they will likely not be able to honor ー the promise to repeal Obamacare. "They can't walk away from a promise they've made for eight years," Politico reporter Adam Cancryn said Tuesday in an interview on Cheddar. Repealing Obamacare "would be even more difficult than it was last year," he added. While Cancryn thinks it will be "a major shock at this point" if Republicans maintain control of both the House and Senate, Senate Majority Leader Mitch McConnell has hinted that the party would consider an attempt to dismantle the Affordable Care Act if it manages to thwart a "blue wave." Although the right failed to repeal Obamacare last year, their efforts to end the program were not penalized ー so they may try their luck again, Cancryn said. "There may be a feeling that if we didn't pay for it the first time, then there's no real harm in taking another shot." Even if Republicans were to successfully repeal Obamacare, the party is far from finding a solution to replace it, Cancryn added. "There's no viable Republican health plan going forward." For full interview [click here](https://cheddar.com/videos/how-the-midterm-elections-could-shape-the-future-of-healthcare-in-america).

Share:
More In Politics
Skydio CEO On Russia-US Drone Collision
Adam Bry, co-founder and CEO of drone manufacturer Skydio, joined Cheddar News to discuss the company's latest funding round and the Russia-US drone collision.
Fed Set to Launch Digital Payments System Over the Summer
The Federal Reserve on Wednesday evening said its long-awaited digital payment system, the FedNow Service, will start operating in July. The service is designed to provide a national platform for financial institutions to settle payments in real-time and at lower cost. That could include large banks, payment processors, and the U.S. Treasury.
Long-Used US Abortion Pill Under Threat in Texas Lawsuit
A federal judge in Texas raised questions Wednesday about a Christian group's effort to overturn the decades-old U.S. approval of a leading abortion drug, in a case that could threaten the country's most common method for ending pregnancies.
Load More